男子非淋菌性尿道炎を対象としたsitafloxacinの一般臨床試験

書誌事項

タイトル別名
  • Clinical study of sitafloxacin in male nongonococcal urethritis

この論文をさがす

抄録

The clinical efficacy and safety of sitafloxacin (STFX), a fluoroquinolone compound, were evaluated in male patients with nongonococcal urethritis treated orally 7 days with 50 mg b.i.d. of STFX. Clinical efficacy was evaluated based on criteria for evaluation of clinical efficacy of antimicrobial agents on urinary tract infection (draft, fourth edition).<BR>Overall clinical efficacy was 88.6%(31/35) for nongonococcal urethritis and, by diagnosis, 85.2%(23/27) for nongonococcal-chlamydial urethritis, 100%(7/7) for Mycoplasma genitalium-negative nongonococcalnonchlamydial urethritis, and excellent in 1 case with M. genitalium-positive nongonococcal urethritis. Eradication by microorganism was 96.0%(24/25) for Chlamydia trachomatis, 88.9%(8/9) for Ureaplasma urealyticum, and 100%(7/7) for Ureaplasma parvum. Two of 3 strains of M. genitalium were eradicated. The incidence of adverse reactions was 27.3%(12/44), the most common being diarrhea. All symptoms were mild or moderate.<BR>Results suggest that STFX was effective and safe in the treatment of male nongonococcal urethritis.

収録刊行物

被引用文献 (2)*注記

もっと見る

参考文献 (11)*注記

もっと見る

詳細情報

問題の指摘

ページトップへ